Maternal and Fetal Complications of Prednisolone Use in Pregnancy
Prednisolone during pregnancy carries minimal additional risk for the mother beyond standard glucocorticoid adverse effects, but poses specific fetal risks including low birth weight, prematurity, and a 3-4 fold increased risk of oral clefts, though overall major malformation risk remains low.
Maternal Complications
Standard Glucocorticoid-Related Risks
The maternal complication profile with prednisolone during pregnancy mirrors that of non-pregnant patients 1. However, pregnant women face compounded risks because pregnancy itself predisposes to conditions that glucocorticoids can worsen:
- Osteoporosis - particularly concerning as pregnancy already increases bone turnover
- Diabetes/hyperglycemia - overlapping with gestational diabetes risk
- Hypertension - compounding preeclampsia risk
Pregnancy-Specific Maternal Complications
Recent large-scale data demonstrates increased risks 2:
- Preeclampsia: 1.72-fold increased risk (95% CI 1.30-2.29)
- Preterm premature rupture of membranes: 1.63-fold increased risk (95% CI 1.01-2.44)
- Pyelonephritis: 4.81-fold increased risk (95% CI 1.18-19.61)
- Venous thromboembolism: 2.50-fold increased risk (95% CI 1.32-4.73)
Important Caveat
The EULAR guidelines note that while the spectrum of adverse effects doesn't differ between pregnant and non-pregnant patients, no robust data exists on whether pregnancy amplifies these risks 1. The evidence level for maternal safety is Category IV (lowest quality).
Fetal/Neonatal Complications
Major Structural Defects
Oral clefts represent the most significant teratogenic risk 3:
- Meta-analysis shows 3.35-fold increased risk of oral clefts (95% CI 1.97-5.69)
- This is consistent with animal studies showing cleft palate formation
- Overall major malformation risk shows marginal increase: odds ratio 3.03 (95% CI 1.08-8.54) when excluding one outlier study
The FDA classifies prednisolone as Pregnancy Category C - animal studies show teratogenicity at human-equivalent doses, but adequate human studies are lacking 4.
Growth and Prematurity
Recent cohort data demonstrates 2:
- Prematurity: 1.51-fold increased risk (95% CI 1.13-2.05)
- Low birth weight/small for gestational age: 2.10-fold increased risk (95% CI 1.34-3.30)
High-dose corticosteroids have consistently caused low birth weight in humans 1, 5.
Neonatal Adrenal Suppression
This risk appears minimal with prednisolone specifically due to placental metabolism:
- Prednisolone is extensively metabolized by placental 11β-hydroxysteroid dehydrogenase type 2, with only ~10% reaching the fetus 1, 5
- A case series of 16 neonates exposed to maternal prednisolone ≥10 mg/day (mean 29.7 mg/day for 18.4 weeks) found no evidence of prolonged HPA axis suppression 6
- When adrenal suppression occurs, it typically presents with early hypoglycemia and late hyponatremia, requiring approximately 3 months of replacement therapy 5
Critical distinction: Dexamethasone and betamethasone are NOT metabolized by the placenta and readily cross to the fetus - these should be avoided for maternal indications 7, 5.
Infection Risk
Neonatal infection rates are not increased with maternal prednisolone exposure (Category IB evidence) 1.
Multiple Course Effects
When multiple courses of antenatal corticosteroids are given 8:
- Increased risk of intrauterine growth restriction
- Increased risk of early-onset neonatal sepsis
- Maternal infections, endometritis, and chorioamnionitis (especially with premature rupture of membranes)
Clinical Monitoring Requirements
Infants born to mothers on corticosteroids must be carefully observed for signs of hypoadrenalism 4. This includes monitoring for:
- Hypoglycemia (most common early sign)
- Hyponatremia (later presentation)
- Poor feeding and lethargy
- Hypotension
Key Management Principles
- Use hydrocortisone preferentially over prednisolone when possible for adrenal insufficiency in pregnancy 7
- Never use dexamethasone for maternal indications - it crosses the placenta freely 7
- Monitor maternal glucose, blood pressure, and weight gain at least once per trimester 7
- Counsel about oral cleft risk - this represents the most significant fetal structural risk
- Expect dose increases particularly in the third trimester (20-40% increase from week 24 onward) 7
- Plan for stress dosing during labor - use hydrocortisone 100 mg IV similar to major surgical stress 7
Breastfeeding Considerations
Prednisolone is excreted minimally into breast milk and breastfeeding is generally safe 1. To minimize infant exposure, avoid breastfeeding during the first 4 hours after prednisolone intake when milk concentrations peak 1.